ÌÇÐÄvlog

This study uses data from the Heath and Retirement Study to measure out-of-pocket costs incurred by Medicare beneficiaries with cancer and identify which factors contribute to high out-of-pocket costs.

This secondary analysis of the TRIO-013 phase 3 randomized clinical trial attempts to determine if gastric acid suppressants such as proton pump inhibitors may impair capecitabine efficacy.

This cohort study uses resected cases from the International Cancer Genome Consortium to classify pancreatic ductal adenocarcinoma according to distinct mutational processes.

This secondary analysis of a randomized clinical trial assesses whether molecular variables improve prognostic classification of glioblastomas treated with radiation and temozolomide.

This randomized clinical trial compares 10-year survival rates for 2 adjuvant combination therapies for early breast cancer: docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil vs docetaxel plus capecitabine followed cyclophosphamide, epirubicin, and capecitabine.

This genomic analysis compares the prevalence and types of mutations in a cohort of black and white patients with lung cancer.

This cross-sectional study of the NHANES 2013-2014 estimates the prevalence of genital human papillomavirus (HPV) infection and the HPV vaccination rate in the United States among adult men and examines potential risk factors for HPV infection.

This study examines the influence of lay navigation on health care spending and resource use among geriatric patients with cancer within an academic health system cancer community network.